Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Company ParticipantsErik Holmlin - President and CEOMark Adamchak - VP of AccountingWebb Campbell - VPConference Call ParticipantsYi Chen - Managing Director and Senior AnalystOperatorGood day, and welcome to the Bionano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.W ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Company ParticipantsErik Holmlin - President and CEOMark Adamchak - VP of AccountingWebb Campbell - VPConference Call ParticipantsYi Chen - Managing Director and Senior AnalystOperatorGood day, and welcome to the Bionano Q4 and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Webb Campbell ...

Bionano Genomics (NasdaqCM:BNGO) Q4 2025 Earnings call March 23, 2026 04:30 PM ET Speaker2Good day, and welcome to the Bionano fourth quarter and full year 2025 earnings conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Webb Campbell from Gilmartin Group. Please go ahead.Speaker3Thank you, Carmen, and good afternoon, everyone. Welcome to Bionano's fourth quarter and full year 2025 financial results conference call. On the call today is Dr. Erik ...

BNGO stock is soaring. See the chart and price action here. Despite a slight year-over-year revenue dip, the stock showed resilience, gaining nearly 27% in Monday’s regular session.The Financials: Narrowing the GapFor the fourth quarter, Bionano reported revenue of $8 million, landing at the high end of its previous guidance. While this was a 3% decrease from the prior year, the real victory was in the margins. Full-year gross margins skyrocketed to 46%, a massive leap from the 1% seen in 2024.The improveme ...

Q4'25 & FY25 Financial Results Webcast & Call March 23, 2026 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for ...

Core Insights - Bionano Genomics showcased the advancements of Optical Genome Mapping (OGM) in addressing constitutional genetic disorders at the Bionano Symposium 2026, emphasizing its unique capabilities in detecting structural variants that traditional methods often miss [1][11] Group 1: OGM Applications and Impact - OGM provides unbiased, comprehensive genome-wide structural variant detection, enhancing the interpretation of complex rearrangements in genetic disorders [2] - The technology is transforming research in rare and unresolved disorders by bridging gaps between cytogenetics and molecular genomics, revealing variants overlooked by conventional methods [3] - In a study on autism spectrum disorder (ASD), OGM identified relevant variants in 24% of cases, demonstrating its effectiveness in detecting complex genetic alterations [4] Group 2: Research Findings and Case Studies - OGM has shown utility in reproductive genetics, uncovering cryptic translocations in recurrent pregnancy loss that traditional karyotyping often misses, thus aiding genetic counseling [5] - Studies highlighted OGM's ability to resolve rare constitutional rearrangements and complex copy number variations, improving understanding in unresolved cases across diverse populations [6] - Research demonstrated OGM's capability to detect structural variants associated with conditions like fascioscapulohumeral muscular dystrophy and infertility, emphasizing the need for population-specific OGM databases [7] Group 3: Statistical Insights - In a cohort of 133 subjects with rare diseases, OGM identified pathogenic or likely pathogenic variants in 20% of subjects, with a notable 12% success rate in subjects previously testing negative by chromosomal microarray analysis and whole exome sequencing [9] Group 4: Symposium Highlights and Future Directions - The symposium featured over 1,200 participants from 73 countries, showcasing the global interest in OGM and its applications in genetic research [1] - Panel discussions focused on best practices for OGM implementation and strategies for resolving complex constitutional disorders, indicating a collaborative approach to advancing genetic research [10] - The ongoing symposium will continue to explore genome landscape analysis and feature a scientific poster competition, highlighting the commitment to innovation in genomic research [12]

Core Insights - Bionano Genomics is showcasing advancements in Optical Genome Mapping (OGM) for hematologic malignancies at the Bionano Symposium 2026, emphasizing its role in enhancing genomic analysis and precision medicine [1][11] Group 1: Event Overview - The Bionano Symposium 2026 has over 1000 registered attendees from 70 countries, making it the largest event dedicated to OGM and Bionano solutions in 2026 [1] - The symposium features global experts discussing how OGM is transforming cytogenetic and molecular workflows in the study of leukemias, lymphomas, and multiple myeloma [1][11] Group 2: Presentations and Findings - Dr. Alka Chaubey presented on the functionality of OGM, highlighting its enhanced resolution and sensitivity compared to traditional methods like karyotyping, FISH, and NGS [2][3] - Dr. Ravindra Kolhe compared OGM with traditional cytogenetic methods, emphasizing the integration of OGM and NGS for comprehensive cancer genomics analysis [4] - Dr. Wahab A. Khan demonstrated OGM's ability to uncover complex structural variants in chronic lymphocytic leukemia that standard methods fail to detect [5] - Amber Verhasselt showcased OGM's effectiveness in identifying pathogenic aberrations in non-Hodgkin lymphoma across various specimen types [6] - Dr. Elly De Vlieghere illustrated how OGM can replace multiple traditional assays in multiple myeloma, providing more comprehensive answers [7] - Dr. Rashmi Kanagal Shamanna presented expert recommendations from the International Consortium of OGM regarding its use in various hematologic malignancy subtypes [8] Group 3: Future Implications - The session concluded with a panel discussion on best practices for implementing OGM in routine research, indicating its growing importance in hematologic malignancy studies [10] - Bionano's leadership expressed optimism about OGM's potential to transform genomic analysis and improve understanding of complex genomic events [11]

Core Viewpoint - Bionano Genomics is hosting the Bionano Symposium 2026, a virtual event focused on optical genome mapping (OGM), showcasing advancements and applications in various research fields [1][2][3] Event Overview - The symposium will take place from February 23-26, 2026, featuring over 30 researchers from North America, Europe, and Asia [2] - The event will include scientific presentations, interactive panel discussions, and a virtual poster hall [2][3] Research Applications - The symposium will cover multiple research applications including hematologic malignancies, solid tumors, bioprocessing, constitutional genetic disorders, and gene and cell therapy [2][4] - Each day will focus on specific topics, such as advancements in hematologic malignancies, new frontiers in oncology research, constitutional genetic disorder research, and the landscape of genome analysis with Bionano products [4][9] Technology and Tools - Bionano will showcase its tools including Ionic, Saphyr, and Stratys systems, along with VIA software for genome analysis [5][6] - Key opinion leaders will discuss various applications of these tools, emphasizing their role in enhancing laboratory workflows and genomic analysis [5][6] Company Mission - Bionano Genomics aims to transform genome analysis through OGM solutions, diagnostic services, and software, positioning itself as a leader in the field [6]

Financial Performance - Revenue reached $7.4 million, a 21% increase compared to Q3 2024[13] - Core revenue increased by 12% compared to Q3 2024[13] - Non-GAAP gross margin improved to 46%, significantly higher than the 26% in Q3 2024[13] - Non-GAAP operating expenses decreased by 40% compared to Q3 2024, totaling $9.7 million[13] Operational Highlights - Flowcells sold increased by 7% to 8,390 compared to Q3 2024[13] - The OGM installed base grew by 4% compared to Q3 2024, reaching 384 systems[13] - Seven new OGM installations were completed in Q3 2025, bringing the year-to-date total to 23[13] Strategic Focus and Outlook - The company completed a $10 million public offering of common stock in September 2025[13] - Cash, cash equivalents, and available-for-sale securities totaled $31.8 million as of September 30, 2025[13] - The company is reiterating its full-year 2025 revenue guidance of $26 - $30 million[30] - The company expects new OGM installations to surpass 25 systems for FY 2025, exceeding prior expectations of 20-25 systems[30]

Group 1 - Bionano Genomics, Inc. has launched a public offering of 5 million shares at a price of $2.00 per share, aiming to generate $10 million in gross proceeds, with potential additional funds of $20 million if warrants are fully exercised [1][2] - The funds from the offering are intended to support general corporate needs and will provide a solid foundation for the company's expansion into clinical and anatomic pathology [2][3] - The company is focusing on enhancing utilization among routine users, strengthening its installed base, accelerating adoption of its VIA software, and developing reimbursement support for its optical genome mapping (OGM) technology [3][4] Group 2 - Bionano Genomics, Inc. is based in San Diego, California, and specializes in genome analysis solutions, aiming to transform the understanding of the genome since its founding in 2003 [4]